A U.S. cannabis company has made a bid to acquire Aurora Cannabis Inc., a company based in Edmonton. Aurora has announced the formation of a special committee to review the unsolicited offer from Curaleaf Holdings Inc., which aims to purchase all shares of Aurora.
Curaleaf, a company headquartered in Stamford, Conn., shared that if successful, the acquisition would create a combined cannabis entity operating in 17 countries across Europe, North America, and other global markets. Despite attempts to privately negotiate with Aurora, Curaleaf decided to go public with its proposal after receiving no response from Aurora’s board following formal communications.
Curaleaf proposed a payment of $4 US per share to Aurora shareholders, along with an additional $0.75 US in cash for each Aurora share. Aurora confirmed receipt of letters from Curaleaf outlining the acquisition proposals but disputed Curaleaf’s claim that Aurora rejected engagement. Aurora mentioned ongoing communication between the companies’ leadership as of July 24.
Aurora plans to establish a special committee of independent directors to assess the bid’s merits and potential benefits for stakeholders. The company emphasized that while discussions are ongoing, there is no guarantee of a finalized deal. Aurora will operate as usual during this period.
Analysts from TD Cowen expressed reservations about the current offer, suggesting that it undervalues Aurora’s long-term business prospects. They highlighted Aurora’s strong position in the medical cannabis market, quality product portfolio, financial stability, and regulatory expertise as factors that could lead to increased value over time.
Curaleaf’s CEO, Boris Jordan, believes that merging the two companies would create synergies by combining Curaleaf’s global distribution capabilities with Aurora’s international medical cannabis operations. The companies have collectively generated over $1.5 billion US in revenue in the past year, with Curaleaf anticipating annual cost savings of at least $40 million US post-acquisition.
Jordan sees the potential merger as a beneficial opportunity for both Curaleaf and Aurora shareholders, offering exposure to a diversified global platform and U.S. regulatory advancements.